Salvia BioElectronics, a clinical-stage medical device company in the Netherlands developing neuromodulation therapy for debilitating migraine, has appointed Jill Schiaparelli as Chair of its Board of Directors. The placement was led by executive search firm Coulter Partners, which specialises in leadership appointments across the life sciences.
Schiaparelli brings nearly three decades of leadership across medical devices, neuromodulation and commercial strategy, a combination directly relevant to a company working to bring a novel migraine therapy from clinical development toward the market. Her experience spans the scientific, regulatory and commercial dimensions that determine whether an emerging medtech company can translate a promising technology into a viable product.
Beyond Salvia, she currently serves on the Board of Directors of OssDsign, a Swedish regenerative-medicine company, and the Global Nerve Foundation, and contributes as a consulting Executive in Residence at the Rockefeller Neuroscience Institute at WVU Medicine. She holds an MBA in finance and business management from the Stern School of Business at New York University and a business degree from Boston University's Questrom School of Business.
For a clinical-stage device company, the composition of the board carries particular weight, since directors help steer the capital-raising, regulatory and commercialisation decisions that shape a company's trajectory. Appointing a chair with deep neuromodulation and commercial experience signals Salvia's intent to strengthen governance as it advances its migraine therapy through development.
The appointment also reflects a broader pattern of experienced US medtech executives taking board roles at European clinical-stage companies, bringing commercial and capital-markets perspective to firms preparing for later-stage growth. How Schiaparelli helps guide Salvia through its clinical and financing milestones will be the measure of her chairmanship in the period ahead.
Neuromodulation has become an active area of medtech investment, as device makers pursue alternatives to drugs for chronic conditions such as migraine, chronic pain and neurological disorders. Clinical-stage companies in the field face the dual challenge of proving efficacy in rigorous trials and building the commercial and regulatory foundations for launch, making experienced board leadership especially valuable.
A chair who has navigated commercialisation and board governance across multiple medtech companies can help a young firm sequence its priorities, from clinical evidence generation to reimbursement strategy and financing. For Salvia, the appointment adds senior, sector-specific oversight at a stage when the decisions made at board level can significantly influence the company's path to market and its ability to attract the capital required to get there.
